IDH1 MUTATION
Clinical trials for IDH1 MUTATION explained in plain language.
Never miss a new study
Get alerted when new IDH1 MUTATION trials appear
Sign up with your email to follow new studies for IDH1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple-drug combo aims to improve leukemia treatment with fewer side effects
Disease control Recruiting nowThis study tests a combination of three drugs (olutasidenib, venetoclax, and azacitidine) in people with a specific genetic subtype of acute myeloid leukemia (IDH1-mutated). The goal is to see if this combo works as well as or better than standard chemotherapy, with fewer side ef…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Justin Watts, MD • Aim: Disease control
Last updated May 16, 2026 16:42 UTC
-
Promising Triple-Drug cocktail targets tough leukemia mutation
Disease control Recruiting nowThis study tests a combination of three drugs—venetoclax, ivosidenib, and azacitidine—in adults with acute myeloid leukemia (AML) that has an IDH1 mutation. The goal is to see if this triple therapy can improve remission rates and survival. About 23 participants will receive the …
Matched conditions: IDH1 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug aims to keep leukemia in remission after transplant
Disease control Recruiting nowThis study tests whether a daily pill called ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It is for people with a specific IDH1 gene mutation. About 75 participants will receive either ivosidenib or a placebo for up to tw…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 15, 2026 11:52 UTC